Simvastatin Improves Outcomes of Endotoxin-induced Coagulopathy by Regulating Intestinal Microenvironment

Abstract

Objective

The systemic inflammatory response is regarded as the major cause of endotoxin-induced coagulopathy, which is a strong predictor of mortality in patients with severe sepsis. Simvastatin plays an important role in reducing inflammation. In addition, the gut has long been hypothesized to be the “motor” of critical illness, driving or aggravating sepsis by the increased intestinal permeability and bacterial translocation. Whether simvastatin plays a role in severe endotoxin-induced coagulopathy through the gut is unclear.

Methods

In this study, mice were administered 20 mg/kg simvastatin by gavage for 2 weeks and then intraperitoneally injected with 50 mg/kg endotoxin. Twelve h later, cytokine release, coagulation dysfunction, organ damage, and survival were assessed. Besides, the intestinal barrier, permeability, bacteria abundance, and translocation were evaluated.

Results

We found that the severity of endotoxin-induced coagulopathy was significantly improved in simvastatin-pretreated mice, who showed attenuated depletion of coagulation factors and platelets, decreased plasminogen activator inhibitor-1 (PAI-1) expression, reduced organ fibrin deposition, and improved survival time. Also, simvastatin reduced epithelial apoptosis and improved intestinal barrier function by upregulating antimicrobial peptides, lysozyme, and mucins. Simvastatin increased Lactobacillales counts, while the lipopolysaccharide group showed increased Desulfovibrio and Mucispirillum, which can produce harmful toxins. Finally, the decreased intestinal permeability in the simvastatin group caused reduced bacterial translocation in the organs and blood, both in terms of quantity and species.

Conclusion

Simvastatin improves the prognosis of severe endotoxemia, and the intestinal microenvironment participates in this process.

Keywords

endotoxemia / endotoxin-induced coagulopathy / simvastatin / inflammatory cytokines / intestinal permeability / intestinal microorganism

References

[1] SingerM, DeutschmanCS, SeymourCW, et al.. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA, 2016, 315(8): 801-810

[2] LeviM, Dörffler-MellyJ, ReitsmaP, et al.. Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein-C-deficient mice. Blood, 2003, 101(12): 4823-4827

[3] GandoS, ShiraishiA, YamakawaK, et al.. Role of disseminated intravascular coagulation in severe sepsis. Thromb Res, 2019, 178: 182-188

[4] Rangel-FraustoMS, PittetD, CostiganM, et al.. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA, 1995, 273(2): 117-123

[5] KumarM, Leon CoriaA, CornickS, et al.. Increased intestinal permeability exacerbates sepsis through reduced hepatic SCD-1 activity and dysregulated iron recycling. Nature Commun, 2020, 11(1): 483

[6] FayKT, FordML, CoopersmithCM. The intestinal microenvironment in sepsis. Biochim Biophys Acta Mol Basis Dis, 2017, 1863(10): 2574-2583

[7] ShimizuK, OguraH, GotoM, et al.. Altered gut flora and environment in patients with severe SIRS. J Trauma, 2016, 60(1): 126-133

[8] MacFieJ, O’BoyleC, MitchellCJ, et al.. Gut origin of sepsis: a prospective study investigating associations between bacterial translocation, gastric microflora, and septic morbidity. Gut, 1999, 452: 223-228

[9] DeitchEA. Bacterial translocation or lymphatic drainage of toxic products from the gut: what is important in human beings?. Surgery, 2002, 131(3): 241-244

[10] ArnaudH, FabienL, VaninaL, et al.. Simvastatin inhibits the pro-inflammatory and pro-thrombotic effects of IL-17 and TNF-α on endothelial cells. Ann Rheum Dis, 2013, 72(5): 754-760

[11] BeigelY, FuchsJ, SnirM, et al.. Lovastatin therapy in hypercholesterolemia: effect on fibrinogen, hemorrheologic parameters, platelet activity, and red blood cell morphology. J Clin Pharmacol, 1991, 31(6): 512-517

[12] MortensenEM, RestrepoMI, CopelandLA, et al.. Impact of previous statin and angiotensin II receptor blocker use on mortality in patients hospitalized with sepsis. Pharmacotherapy, 2007, 27(12): 1619-1626

[13] MerxMW, LiehnEA, JanssensU, et al.. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation, 2004, 109(21): 2560-2565

[14] ShihCC, HsuLP, LiaoMH, et al.. Effects of SPAK on vascular reactivity and nitric oxide production in endotoxemic mice. Eur J Pharmacology, 2017, 814: 248-254

[15] HeX, ZhengN, HeJ, et al.. Gut Microbiota Modulation Attenuated the Hypolipidemic Effect of Simvastatin in High-Fat/Cholesterol-Diet Fed Mice. J Proteome Res, 2017, 16(5): 1900-1910

[16] CaniPD, BibiloniR, KnaufC, et al.. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes, 2008, 57(6): 1470-1481

[17] HuseSM, WelchDM, MorrisonHG, et al.. Ironing out the wrinkles in the rare biosphere through improved OTU clustering. Environ Microbiol, 2010, 12(7): 1889-1898

[18] CoopersmithCM, StrombergPE, DunneWM, et al.. Inhibition of intestinal epithelial apoptosis and survival in a murine model of pneumonia-induced sepsis. JAMA, 2002, 287(13): 1716-1721

[19] BergstromKS, Kissoon-SinghV, GibsonDL, et al.. Muc2 protects against lethal infectious colitis by disassociating pathogenic and commensal bacteria from the colonic mucosa. PLoS Pathog, 2010, 6(5): e1000902

[20] XiaL. Core 3-derived O-glycans are essential for intestinal mucus barrier function. Meth Enzymol, 2010, 479: 123-141

[21] FrancoRF, de JongeE, DekkersPE, et al.. The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: relationship with activation of coagulation. Blood, 2000, 96(2): 554-559

[22] EtoM, KozaiT, CosentinoF, et al.. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation, 2002, 105(15): 1756-1759

[23] PathakR, GhoshSP, ZhouD, et al.. The Vitamin E Analog Gamma-Tocotrienol (GT3) and Statins Synergistically Up-Regulate Endothelial Thrombomodulin (TM). Int J Mol Sci, 2016, 17(11): 1937

[24] SahebkarA, CatenaC, RayKK, et al.. Impact of statin therapy on plasma levels of plasminogen activator inhibitor-1. A systematic review and meta-analysis of randomised controlled trials. Thromb Haemost, 2016, 116(1): 162-171

[25] ChinaekeEE, LoveBL, MagagnoliJ, et al.. The impact of statin use prior to intensive care unit admission on critically ill patients with sepsis. Pharmacotherapy, 2021, 41(2): 162-171

[26] HanX, FinkMP, DeludeRL. Proinflammatory cytokines cause NO*-dependent and -independent changes in expression and localization of tight junction proteins in intestinal epithelial cells. Shock, 2003, 19(3): 229-237

[27] HanX, FinkMP, YangR, et al.. Increased iNOS activity is essential for intestinal epithelial tight junction dysfunction in endotoxemic mice. Shock, 2004, 21(3): 261-270

[28] FarhadiA, KeshavarzianA, RanjbaranZ, et al.. The role of protein kinase C isoforms in modulating injury and repair of the intestinal barrier. J Pharmacol Exp Ther, 2006, 316(1): 1-7

[29] ScottKG, MeddingsJB, KirkDR, et al.. Intestinal infection with Giardia spp. reduces epithelial barrier function in a myosin light chain kinase-dependent fashion. Gastroenterology, 2002, 123(4): 1179-1190

[30] PengH, LuoP, LiY, et al.. Simvastatin alleviates hyperpermeability of glomerular endothelial cells in early-stage diabetic nephropathy by inhibition of RhoA/ ROCK1. PLoS ONE, 2013, 8(11): e80009

[31] GongX, MaY, RuanY, et al.. Long-term atorvastatin improves age-related endothelial dysfunction by ameliorating oxidative stress and normalizing eNOS/ iNOS imbalance in rat aorta. Exp Gerontol, 2014, 52: 9-17

[32] TrivediK, BarrettKE, Resta-LenertSC. Probiotic inhibition of the entry of enteroinvasive E. coli into, human intestinal epithelial cells involves both Rho-dependent and -independent pathways. Gastroenterology, 2003, 124(4): A106-A106

[33] TakadaK, OhnoN, YadomaeT. Detoxification of lipopolysaccharide (LPS) by egg white lysozyme. FEMS Immunol Med Microbiol, 1994, 9(4): 255-263

[34] EstakiM, DeCoffeD, GibsonDL. Interplay between intestinal alkaline phosphatase, diet, gut microbes and immunity. World J Gastroenterol, 2014, 20(42): 15 650-15 656

[35] VaishnavaS, YamamotoM, SeversonKM, et al.. The antibacterial lectin RegIIIgamma promotes the spatial segregation of microbiota and host in the intestine. Science, 2011, 334(6053): 255-258

[36] Caparrós-MartínJA, LareuRR, RamsayJP, et al.. Statin therapy causes gut dysbiosis in mice through a PXRdependent mechanism. Microbiome, 2017, 5(1): 95

[37] PanigrahiP, ParidaS, NandaNC, et al.. A randomized synbiotic trial to prevent sepsis among infants in rural India. Nature, 2017, 548(7668): 407-412

[38] ShimizuK, YamadaT, OguraH, et al.. Synbiotics modulate gut microbiota and reduce enteritis and ventilator-associated pneumonia in patients with sepsis: a randomized controlled trial. Crit Care, 2018, 22(1): 239

[39] WeiZS, AugustoLA, ZhaoLP, et al.. Desulfovibrio desulfuricans isolates from the gut of a single individual: structural and biological lipid A characterization. FEBS Lett, 2014, 589(1): 165-171

[40] BelzerC, GerberGK, RoeselersG, et al.. Dynamics of the microbiota in response to host infection. PLoS ONE, 2014, 9(7): e95534

[41] NolanJA, SkuseP, GovindarajanK, et al.. The influence of rosuvastatin on the gastrointestinal microbiota and host gene expression profiles. Am J Physiol Gastrointest Liver Physiol, 2017, 312(5): G488-G497

[42] CekanaviciuteE, YooBB, RuniaTF, et al.. Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proc Natl Acad Sci USA, 2017, 114(40): 10713-10718